Intraoperative Hemoadsorption in Patients With Native Mitral Valve Infective Endocarditis.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
09 2020
Historique:
received: 16 05 2019
revised: 04 12 2019
accepted: 26 12 2019
pubmed: 16 2 2020
medline: 3 11 2020
entrez: 16 2 2020
Statut: ppublish

Résumé

Cardiac surgery in patients with infective endocarditis is associated with high mortality owing to postoperative septic multiorgan failure. Hemoadsorption therapy may improve surgical outcomes by reducing the circulating cytokines. We aimed to evaluate the clinical effects of intraoperative hemoadsorption in patients with mitral valve endocarditis. Eligible candidates were patients with infective endocarditis of the native mitral valve undergoing cardiac surgery between January 2014 and July 2018. Patients with intraoperative hemoadsorption (hemoadsorption) were compared with surgery without hemoadsorption (control). The end points were the incidence of postoperative sepsis, sepsis-associated death, and 30-day mortality. Furthermore, postoperative need for epinephrine and norepinephrine and systemic vascular resistance were evaluated. A total of 58 consecutive patients were included: 30 in the hemoadsorption group and 28 in the control group. Postoperative sepsis occurred in 5 patients in the hemoadsorption group and in 11 in the control group (P = .05). No sepsis-associated death occurred in the hemoadsorption group, whereas five septic patients in the control group died (P = .02). Thirty-day mortality was 10% in the hemoadsorption group versus 18% in the control group (P = .39). On intensive care unit admission, the cumulative need for epinephrine and norepinephrine was 0.15 versus 0.24 μg/kg body weight/min (P = .01) and the median systemic vascular resistance was 1413 versus 1010 dyn·s·cm Intraoperative hemoadsorption might reduce the incidence of postoperative sepsis and sepsis-related death. In addition, patients with intraoperative hemoadsorption showed greater hemodynamic stability. These data suggest that intraoperative hemoadsorption may improve surgical outcome in patients with mitral valve endocarditis.

Sections du résumé

BACKGROUND
Cardiac surgery in patients with infective endocarditis is associated with high mortality owing to postoperative septic multiorgan failure. Hemoadsorption therapy may improve surgical outcomes by reducing the circulating cytokines. We aimed to evaluate the clinical effects of intraoperative hemoadsorption in patients with mitral valve endocarditis.
METHODS
Eligible candidates were patients with infective endocarditis of the native mitral valve undergoing cardiac surgery between January 2014 and July 2018. Patients with intraoperative hemoadsorption (hemoadsorption) were compared with surgery without hemoadsorption (control). The end points were the incidence of postoperative sepsis, sepsis-associated death, and 30-day mortality. Furthermore, postoperative need for epinephrine and norepinephrine and systemic vascular resistance were evaluated.
RESULTS
A total of 58 consecutive patients were included: 30 in the hemoadsorption group and 28 in the control group. Postoperative sepsis occurred in 5 patients in the hemoadsorption group and in 11 in the control group (P = .05). No sepsis-associated death occurred in the hemoadsorption group, whereas five septic patients in the control group died (P = .02). Thirty-day mortality was 10% in the hemoadsorption group versus 18% in the control group (P = .39). On intensive care unit admission, the cumulative need for epinephrine and norepinephrine was 0.15 versus 0.24 μg/kg body weight/min (P = .01) and the median systemic vascular resistance was 1413 versus 1010 dyn·s·cm
CONCLUSIONS
Intraoperative hemoadsorption might reduce the incidence of postoperative sepsis and sepsis-related death. In addition, patients with intraoperative hemoadsorption showed greater hemodynamic stability. These data suggest that intraoperative hemoadsorption may improve surgical outcome in patients with mitral valve endocarditis.

Identifiants

pubmed: 32059855
pii: S0003-4975(20)30188-0
doi: 10.1016/j.athoracsur.2019.12.067
pii:
doi:

Substances chimiques

Biomarkers 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

890-896

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Zaki Haidari (Z)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany. Electronic address: zaki.haidari@uk-essen.de.

Daniel Wendt (D)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany.

Matthias Thielmann (M)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany.

Malwina Mackowiak (M)

Department of Mathematics and Technique, Koblenz University of Applied Science, RheinAhrCampus Remagen, Remagen, Germany.

Markus Neuhäuser (M)

Department of Mathematics and Technique, Koblenz University of Applied Science, RheinAhrCampus Remagen, Remagen, Germany.

Heinz Jakob (H)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany.

Arjang Ruhparwar (A)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany.

Mohamed El-Gabry (M)

Department of Thoracic and Cardiovascular Surgery, West-German Heart and Vascular Centre, University Hospital Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH